达雷木单抗联合硼替佐米地塞米松改善复发难治性骨髓瘤无进展生存.pdfVIP

CASTOR:DaratumumabAdded

toBortezomib/Dexamethasone

ImprovesPFS,ResponseinRR

Myeloma

CCOtConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-7,2016

*CCOisantmedicaleducationcompanythatprovidesstate-of-the-artmedical

informationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.

ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorporation,Genentech,

Incyte,Merck,andTaihoPharmaceuticals.

CASTOR:StudyBackground

▪Daratumumab:novelhumananti-CD38IgGmonoclonal

antibody

–Exertsdirectandindirectantimyelomaactivity

–DepletesCD38+immunosuppressiveregulatorycells

–PromotesT-cellexpansionandactivation

–Approvedasasingleagentinrelapsed/refractoryMM

▪CASTOR:randomized,open-label,active-controlled

phaseIIItrialdesignedtoassessbenefitofadding

daratumumabtobortezomib/dexamethasone(current

standardofcare)inptswithrelapsed/refractoryMM

PalumboA,etal.ASCO2016.LBA4.Slidecredit:

CASTOR:StudyDesign

PhaseIIIstudy

Daratumumab16mg/kg

Cyc1-3Q7D,4-8Q21D,9+Q28D

2

Bortezomib1.3mg/mSC

Ptswith

Cyc1-8,Days1,4,8,11

relapsed/refractoryMMDexamethasone20mg

whoreceived≥1priorCyc1-8,Days1,2,4,5,8,9,11,12

regimenincluding(n251)Medianfollow-up:

bortezomib(butnot